Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
V114 followed by PNEUMOVAX 23 in healthy adults (PNEU-PATH)
NCT03480763Phase 3Completed
- Sponsor
- Merck & Co.
- Start
- Jun 2018
- Primary completion
- Dec 2019
- Modality
- Split/Subunit Vaccines
- Countries
- 4
01
Overview
A Phase 3 trial of pneumococcal 15-valent conjugate vaccine in pneumococcal infection, sponsored by Merck & Co.. Started Jun 2018; status: completed.
02
Drugs
pneumococcal 15-valent conjugate vaccine
03
Conditions
pneumococcal infection
Beyond the preview
Go deeper on NCT03480763.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03480763.